TipRanks
Advertisement
Advertisement
Oric Pharmaceuticals initiated with a Buy at BTIG
PremiumThe FlyOric Pharmaceuticals initiated with a Buy at BTIG
15d ago
Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright
Premium
The Fly
Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright
2M ago
ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside
Premium
Ratings
ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside
2M ago
Oric Pharmaceuticals resumed with a Buy at Stifel
PremiumThe FlyOric Pharmaceuticals resumed with a Buy at Stifel
4M ago
Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained
Premium
Ratings
Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained
4M ago
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
Premium
Ratings
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
5M ago
Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
PremiumThe FlyOric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
6M ago
Oric selloff brings attractive entry point, says H.C. Wainwright
Premium
The Fly
Oric selloff brings attractive entry point, says H.C. Wainwright
6M ago
Oric Pharmaceuticals should be bought on selloff, says Citi
Premium
The Fly
Oric Pharmaceuticals should be bought on selloff, says Citi
6M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―